GLP-1 Receptor Antagonist Weight Loss: A Comprehensive Overview
The Emergence of GLP-1 Receptor Antagonists in Weight Loss Treatment

Advances in GLP-1 Receptor Antagonist Research



4 days agoGlucagon-like peptide-1 (GLP-1)receptoragonists may be more effective in women than in men, according to research published in JAMA Internal Medicine.
Feb 5, 2026What areGLP-1s?GLP-1receptoragonists work by targetingGLP-1receptors: increasing insulin, decreasing glucagon and delaying gastric emptying. Originally developed for use in type 2 diabetes mellitus,GLP-1sare increasingly being licensed forweight-lossand other cardiometabolic applications. Some newer drugs combineGLP-1receptoragonists with other metabolic targets or additional ...
Glucagon-like peptide-1receptoragonists (GLP-1RAs) are new drugs for the treatment of obesity.
Mar 5, 2025Glucagon-like peptide-1receptoragonists (GLP-1RAs) have transformed obesity management, offering substantialweightlossand metabolic benefits. This review examines their expanding role, evaluating efficacy compared to alternative treatments, emerging indications, ongoing challenges, and future directions. Beyond obesity and type 2 diabetes, the therapeutic potential ofGLP-1RAs extends ...
6 days agoWhat is already known on this topic Use of glucagon-like peptide1receptoragonists (GLP-1RAs) is associated withweightlossand a reduced risk of cardiovascular disease DiscontinuingGLP-1RA treatment is common, and is often followed byweightregain and a rebound in inflammation, both of which are major drivers of the risk of cardiovascular disease
This systematic review evaluates the long-term efficacy and safety ofGLP-1receptoragonists in the management of obesity, focusing on data from high-quality randomized controlled trials published between 2018 and 2025. This review synthesizes ...
1 day agoWhat Science Currently Tells Us About Long-termGLP-1Use & Side EffectsGLP-1receptoragonists like semaglutide and tirzepatide (a dual GLP-1/GIP agonist) have been used to treat type 2 diabetes for roughly two decades, and their FDA-approved role inweightmanagement has expanded significantly in recent years.
Nov 14, 2024Benefits beyondweightlossAlong with helping to control blood sugar and boostingweightloss,GLP-1agonists and SGLT-2 inhibitors seem to have other health benefits. Research has found that some of these medicines may lower the risk of certain serious health conditions, such as kidney disease, heart disease, heart failure and stroke.
7 days agoAreGLP-1agonists psychiatric drugs? The neuroscience of reward, new addiction trial data, and a dosing hypothesis that reframes anhedonia.
Jan 26, 2026The US Food and Drug Administration (FDA) approval of multiple glucagon-like peptide-1 (GLP-1)receptoragonists forweightmanagement has ushered in a new chapter for obesity care. Featuring diverse mechanisms of action, these drugs offer more effective solutions for long-term obesity management even as additional data on their long-term use is slowly being uncovered. "Several randomized ...
Jun 1, 2025Abstract Glucagon-like peptide-1 (GLP-1)receptoragonists (RAs) have become central in managing obesity and type 2 diabetes, primarily through appetite suppression and metabolic regulation. This review explores the mechanisms underlyingGLP-1RA-inducedweightloss, focusing on central and peripheral pathways.
Mar 5, 2026Within three weeks of their launch in the United States on Jan. 5, 2026, the newly approvedGLP-1pills forweightlosshad been prescribed to about 170,000 people, outpacing the rate of adoption of otherGLP-1medications. Previously,GLP-1medications — which mimic the naturally occurring hormone glucagon-like peptide-1, which regulates blood sugar, digestion, and hunger — had been ...
Dec 30, 2025By mimicking the effects of these hormones, retatrutide helps you loseweightby suppressing your appetite, slowing digestion, and helping your body break down fat more effectively. Because of this, retatrutide is thought to be more effective than Wegovy, which only binds toGLP-1receptors, and Mounjaro, which is a dual agonist that mimics the effects ofGLP-1and GIP.
Feb 6, 2026The body's hormone lasts only 20 to 30 minutes, Drucker says. Injected semaglutide binds to theseGLP-1receptorsand reduces appetite for nearly a week, ultimately causing people to eat less ...